FORM 4	4
--------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ⁺ SHERWIN STEPHEN A	2. Issuer Name and RIGEL PHARM			· ·		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (N CELL GENESYS, INC.,, 400 OYSTER BLVD., STE. 525		3. Date of Earliest Transaction (Month/Day/Year) 05/29/2009						Officer (give title below)O	her (specify belo	ow)	
(Street) SOUTH SAN FRANCISCO, CA 94080		4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	1	Fable I - No	on-De	rivative S	ecuritie	s Acqı	ired, Disposed of, or Beneficially Ow	ned		
(Instr. 3) Date	Fransaction te onth/Day/Year)	Execution Date, if	Date, if Code (Instr. 8)		*		of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Form: Direct (D) or Indirect (I)	Beneficial Ownership	
			Code	V	Amount	(D)	Price		(Instr. 4)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(<i>e.g.</i> , puts, calls, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed			6. Date Exercisable and		7. Title and Amount		8. Price of	9. Number of	10.	11. Nature		
	Conversion		· · · · ·	Transact	ransaction of Derivative E		Expiration Date		of Underlying		Derivative	Derivative	Ownership	of Indirect	
Security	or Exercise	(Month/Day/Year)	any	Code			(Month/Day/Year)		Securities		Security			Beneficial	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)					(Instr. 3 and 4)		(Instr. 5)	Beneficially	Derivative	Ownership	
	Derivative				or Disposed							Owned	~	(Instr. 4)	
	Security			of (D)								Direct (D)			
				(Instr. 3, 4,							1	or Indirect			
						and 5)							Transaction(s)	< / <	
											Amount		(Instr. 4)	(Instr. 4)	
								Date	Expiration		or				
								Exercisable		Title	Number				
									Dute		of				
				Code	V	(A)	(D)				Shares				
Stock															
Option										Common					
	\$ 8.12	05/29/2009		Α		10,000		<u>(1)</u>	05/29/2019	Common Stock	10,000	\$ 0	10,000	D	
(Right										Stock					
to Buy)															

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
SHERWIN STEPHEN A CELL GENESYS, INC., 400 OYSTER PT. BLVD., STE. 525 SOUTH SAN FRANCISCO, CA 94080	Х						

Signatures

 /s/ Dolly Vance (Attorney-In-Fact)
 05/29/2009

 Signature of Reporting Person
 Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly over twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.